385 filings
Page 6 of 20
DEFA14A
li996ug 0v
16 Feb 22
Additional proxy soliciting materials
5:04pm
DEFA14A
klu2gozqknxc6j zhl
16 Feb 22
Additional proxy soliciting materials
7:17am
8-K
ovm5ebw9il3w zi1exu
16 Feb 22
Results of Operations and Financial Condition
7:05am
DEFA14A
75zzfgk6ff557fiey4ps
11 Jan 22
Additional proxy soliciting materials
7:02am
8-K
bzm9xbd7zg q9
11 Jan 22
Regulation FD Disclosure
7:00am
8-K
bt9411
19 Nov 21
Alkermes Announces the Appointment of Cato T. Laurencin, M.D., Ph.D. to its Board of Directors
7:08am
8-K
jwn6 j301gl3
8 Nov 21
Alkermes Announces Receipt of Notices of Partial Termination From Janssen Pharmaceutica
4:17pm
8-K
bjb8v7av31bzmd0
27 Oct 21
Alkermes plc Reports Third Quarter 2021 Financial Results
7:05am
S-8
2vmtxc lwp0ukzraep
28 Jul 21
Registration of securities for employees
4:19pm
8-K
ad1t00sqlzojaav
28 Jul 21
Alkermes plc Reports Second Quarter 2021 Financial Results
7:05am
8-K
2zd 0l5k5cq77
14 Jun 21
Departure of Directors or Certain Officers
4:23pm
DEFA14A
q643tm
8 Jun 21
Additional proxy soliciting materials
4:15pm
8-K
gu6jrpf
1 Jun 21
Alkermes Announces FDA Approval of LYBALVI™ for the Treatment of Schizophrenia and Bipolar I Disorder
7:09am
DEFA14A
5sxlrm5
20 May 21
Additional proxy soliciting materials
7:11am
8-K
3v97j
20 May 21
Alkermes Announces the Appointment of Emily Peterson Alva to its Board of Directors
7:10am